Cargando…

Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer

Anaplastic thyroid cancer (ATC) is the most malignant and aggressive of all classifications of thyroid cancer. ATC normally has poor prognosis after classic treatments such as surgery, endocrine therapy, radiotherapy and chemotherapy. Herein, a novel nanocomposite (named as UCNP@PDA@LEN) has been sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jingjing, Ma, Lina, Li, Zhenshengnan, Chen, Bowen, Wu, Yue, Meng, Xianying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483932/
https://www.ncbi.nlm.nih.gov/pubmed/37692340
http://dx.doi.org/10.1039/d3ra02121a
_version_ 1785102492024963072
author Zhou, Jingjing
Ma, Lina
Li, Zhenshengnan
Chen, Bowen
Wu, Yue
Meng, Xianying
author_facet Zhou, Jingjing
Ma, Lina
Li, Zhenshengnan
Chen, Bowen
Wu, Yue
Meng, Xianying
author_sort Zhou, Jingjing
collection PubMed
description Anaplastic thyroid cancer (ATC) is the most malignant and aggressive of all classifications of thyroid cancer. ATC normally has poor prognosis after classic treatments such as surgery, endocrine therapy, radiotherapy and chemotherapy. Herein, a novel nanocomposite (named as UCNP@PDA@LEN) has been synthesized for chemo-photothermal therapy of ATC, which is based on a NaErF(4):Tm(3+)@NaYbF(4)@NaYF(4):Nd(3+) upconverting nanoparticle (UCNP) as the core, a near-infrared light (NIR)-absorbing polydopamine (PDA) as the shell, and lenvatinib (LEN) as a chemotherapeutic drug. The as-prepared multifunctional UCNP@PDA@LEN exhibits excellent photothermal conversion capability (η = 30.7%), good photothermal stability and reasonable biocompatibility. Owing to the high UCL emission and good tumor accumulation ability, the UCL imaging of mouse-bearing ATC (i.e., C643 tumor) has been achieved by UCNP@PDA@LEN. Under 808 nm NIR laser irradiation, the UCNP@PDA@LEN shows a synergistic interaction between photothermal therapy (PTT) and chemotherapy (CT), resulting in strongly suppressed mouse-bearing C643 tumor. The results provide an explicit approach for developing theranostics with high anti-ATC efficiency.
format Online
Article
Text
id pubmed-10483932
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-104839322023-09-08 Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer Zhou, Jingjing Ma, Lina Li, Zhenshengnan Chen, Bowen Wu, Yue Meng, Xianying RSC Adv Chemistry Anaplastic thyroid cancer (ATC) is the most malignant and aggressive of all classifications of thyroid cancer. ATC normally has poor prognosis after classic treatments such as surgery, endocrine therapy, radiotherapy and chemotherapy. Herein, a novel nanocomposite (named as UCNP@PDA@LEN) has been synthesized for chemo-photothermal therapy of ATC, which is based on a NaErF(4):Tm(3+)@NaYbF(4)@NaYF(4):Nd(3+) upconverting nanoparticle (UCNP) as the core, a near-infrared light (NIR)-absorbing polydopamine (PDA) as the shell, and lenvatinib (LEN) as a chemotherapeutic drug. The as-prepared multifunctional UCNP@PDA@LEN exhibits excellent photothermal conversion capability (η = 30.7%), good photothermal stability and reasonable biocompatibility. Owing to the high UCL emission and good tumor accumulation ability, the UCL imaging of mouse-bearing ATC (i.e., C643 tumor) has been achieved by UCNP@PDA@LEN. Under 808 nm NIR laser irradiation, the UCNP@PDA@LEN shows a synergistic interaction between photothermal therapy (PTT) and chemotherapy (CT), resulting in strongly suppressed mouse-bearing C643 tumor. The results provide an explicit approach for developing theranostics with high anti-ATC efficiency. The Royal Society of Chemistry 2023-09-07 /pmc/articles/PMC10483932/ /pubmed/37692340 http://dx.doi.org/10.1039/d3ra02121a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Zhou, Jingjing
Ma, Lina
Li, Zhenshengnan
Chen, Bowen
Wu, Yue
Meng, Xianying
Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
title Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
title_full Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
title_fullStr Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
title_full_unstemmed Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
title_short Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
title_sort synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483932/
https://www.ncbi.nlm.nih.gov/pubmed/37692340
http://dx.doi.org/10.1039/d3ra02121a
work_keys_str_mv AT zhoujingjing synthesisoflenvatinibloadedupconversionpolydopaminenanocompositesforupconversionluminescenceimagingguidedchemophotothermalsynergistictherapyofanaplasticthyroidcancer
AT malina synthesisoflenvatinibloadedupconversionpolydopaminenanocompositesforupconversionluminescenceimagingguidedchemophotothermalsynergistictherapyofanaplasticthyroidcancer
AT lizhenshengnan synthesisoflenvatinibloadedupconversionpolydopaminenanocompositesforupconversionluminescenceimagingguidedchemophotothermalsynergistictherapyofanaplasticthyroidcancer
AT chenbowen synthesisoflenvatinibloadedupconversionpolydopaminenanocompositesforupconversionluminescenceimagingguidedchemophotothermalsynergistictherapyofanaplasticthyroidcancer
AT wuyue synthesisoflenvatinibloadedupconversionpolydopaminenanocompositesforupconversionluminescenceimagingguidedchemophotothermalsynergistictherapyofanaplasticthyroidcancer
AT mengxianying synthesisoflenvatinibloadedupconversionpolydopaminenanocompositesforupconversionluminescenceimagingguidedchemophotothermalsynergistictherapyofanaplasticthyroidcancer